FDA’s Overreach on Compounded Peptides: Legal Battles and How Clinics Can Push Back
Introduction: Peptide therapies like BPC-157, TB-500 (Thymosin Beta-4), CJC-1295, and other short proteins have exploded in popularity across med spas, […]
Featured
WOUND CARE UPDATE: CY 2026 Medicare Physician Fee Schedule Final Rule (CMS1832F)
Published November 5, 2025 • Effective January 1, 2026 This update explains the new Medicare rule in clear terms and
CMS Withdraws Final Skin Substitute LCDs; 2026 Oversight and Payment Reforms Remain the Operative Risk Environment
CMS has announced that its A/B Medicare Administrative Contractors (MACs) have withdrawn, effective immediately, the “final” Local Coverage Determinations (LCDs)
Charges Dismissed Against Whistleblower Physician — A Victory for Transparency and a Reminder on HIPAA Compliance
The U.S. Department of Justice (DOJ) dismissed all charges against Dr. Eithan Haim, who blew the whistle on pediatric transgender
Chapman Predicts Stark Infested Waters For 2025
By Ronald W. Chapman II As a lawyer who has defended healthcare professionals across the country, I’ve seen firsthand how
Advanced Wound Care Products, Big Medicare Dollars & The Kickback Trap
From audits resulting in significant overpayment demands to indictments for alleged violations of the Anti-Kickback Statute, wound care providers are
FDA’s “Held for Sale” Interpretation: Device Reuse in Physician Offices and FDCA Liability
Practicing and hospital-based physicians may be surprised to learn that the Federal Food, Drug, and Cosmetic Act (FDCA) can extend
False Claims Act Statistical Sampling & Extrapolation: Case Law and Guidance
Statistical sampling and extrapolation are methods used by the Office of Inspector General (OIG) and Medicare Administrative Contractors (MACs) to
DEA’s Proposed Telemedicine Rules: What Doctors Need to Know (and Why It Might Get Complicated)
By Ronald W. Chapman II, Safe Harbor Group The Drug Enforcement Administration (DEA) has been working (some might say scrambling) to craft
